Cue Biopharma (NASDAQ:CUE) Shares Gap Down – Here’s Why

Cue Biopharma, Inc. (NASDAQ:CUE) gapped down before the market opened on Friday . The stock had previously closed at $16.6260, but opened at $11.06. Cue Biopharma shares last traded at $15.5140, with a volume of 90,443 shares.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Cue Biopharma in a research note on Friday, March 27th. Wall Street Zen raised shares of Cue Biopharma to a “buy” rating in a research note on Saturday, April 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cue Biopharma has a consensus rating of “Sell”.

Cue Biopharma Price Performance

The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -50.25 and a beta of 1.57. The business’s fifty day simple moving average is $0.34 and its 200 day simple moving average is $0.45.

Cue Biopharma (NASDAQ:CUE) last issued its quarterly earnings data on Monday, March 16th. The company reported $0.30 earnings per share (EPS) for the quarter. Cue Biopharma had a negative net margin of 96.85% and a negative return on equity of 165.19%. The firm had revenue of $21.94 million during the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. boosted its holdings in Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after purchasing an additional 73,000 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Cue Biopharma during the third quarter worth about $62,000. Stifel Financial Corp boosted its holdings in Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc boosted its holdings in Cue Biopharma by 1,231.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its holdings in Cue Biopharma by 15.3% during the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares during the last quarter. 35.04% of the stock is currently owned by hedge funds and other institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.